Background This bibliometric analysis examines the top 50 most-cited articles on COVID-19 complications, offering insights into the multifaceted impact of the virus. Since its emergence in Wuhan in December 2019, COVID-19 has evolved into a global health crisis, with over 770 million confirmed cases and 6.9 million deaths as of September 2023. Initially recognized as a respiratory illness causing pneumonia and ARDS, its diverse complications extend to cardiovascular, gastrointestinal, renal, hematological, neurological, endocrinological, ophthalmological, hepatobiliary, and dermatological systems. Methods Identifying the top 50 articles from a pool of 5940 in Scopus, the analysis spans November 2019 to July 2021, employing terms related to COVID-19 and complications. Rigorous review criteria excluded non-relevant studies, basic science research, and animal models. The authors independently reviewed articles, considering factors like title, citations, publication year, journal, impact factor, authors, study details, and patient demographics. Results The focus is primarily on 2020 publications (96%), with all articles being open-access. Leading journals include The Lancet, NEJM, and JAMA, with prominent contributions from Internal Medicine (46.9%) and Pulmonary Medicine (14.5%). China played a major role (34.9%), followed by France and Belgium. Clinical features were the primary study topic (68%), often utilizing retrospective designs (24%). Among 22,477 patients analyzed, 54.8% were male, with the most common age group being 26–65 years (63.2%). Complications affected 13.9% of patients, with a recovery rate of 57.8%. Conclusion Analyzing these top-cited articles offers clinicians and researchers a comprehensive, timely understanding of influential COVID-19 literature. This approach uncovers attributes contributing to high citations and provides authors with valuable insights for crafting impactful research. As a strategic tool, this analysis facilitates staying updated and making meaningful contributions to the dynamic field of COVID-19 research. Methods A bibliometric analysis of the most cited articles about COVID-19 complications was conducted in July 2021 using all journals indexed in Elsevier’s Scopus and Thomas Reuter’s Web of Science from November 1, 2019 to July 1, 2021. All journals were selected for inclusion regardless of country of origin, language, medical speciality, or electronic availability of articles or abstracts. The terms were combined as follows: (“COVID-19” OR “COVID19” OR “SARS-COV-2” OR “SARSCOV2” OR “SARS 2” OR “Novel coronavirus” OR “2019-nCov” OR “Coronavirus”) AND (“Complication” OR “Long Term Complication” OR “Post-Intensive Care Syndrome” OR “Venous Thromboembolism” OR “Acute Kidney Injury” OR “Acute Liver Injury” OR “Post COVID-19 Syndrome” OR “Acute Cardiac Injury” OR “Cardiac Arrest” OR “Stroke” OR “Embolism” OR “Septic Shock” OR “Disseminated Intravascular Coagulation” OR “Secondary Infection” OR “Blood Clots” OR “Cytokine Release Syndrome” OR “Paediatric Inflammatory Multisystem Syndrome” OR “Vaccine Induced Thrombosis with Thrombocytopenia Syndrome” OR “Aspergillosis” OR “Mucormycosis” OR “Autoimmune Thrombocytopenia Anaemia” OR “Immune Thrombocytopenia” OR “Subacute Thyroiditis” OR “Acute Respiratory Failure” OR “Acute Respiratory Distress Syndrome” OR “Pneumonia” OR “Subcutaneous Emphysema” OR “Pneumothorax” OR “Pneumomediastinum” OR “Encephalopathy” OR “Pancreatitis” OR “Chronic Fatigue” OR “Rhabdomyolysis” OR “Neurologic Complication” OR “Cardiovascular Complications” OR “Psychiatric Complication” OR “Respiratory Complication” OR “Cardiac Complication” OR “Vascular Complication” OR “Renal Complication” OR “Gastrointestinal Complication” OR “Haematological Complication” OR “Hepatobiliary Complication” OR “Musculoskeletal Complication” OR “Genitourinary Complication” OR “Otorhinolaryngology Complication” OR “Dermatological Complication” OR “Paediatric Complication” OR “Geriatric Complication” OR “Pregnancy Complication”) in the Title, Abstract or Keyword. A total of 5940 articles were accessed, of which the top 50 most cited articles about COVID-19 and Complications of COVID-19 were selected through Scopus. Each article was reviewed for its appropriateness for inclusion. The articles were independently reviewed by three researchers (JRP, MAM and TS) (Table 1). Differences in opinion with regard to article inclusion were resolved by consensus. The inclusion criteria specified articles that were focused on COVID-19 and Complications of COVID-19. Articles were excluded if they did not relate to COVID-19 and or complications of COVID-19, Basic Science Research and studies using animal models or phantoms. Review articles, Viewpoints, Guidelines, Perspectives and Meta-analysis were also excluded from the top 50 most-cited articles (Table 1). The top 50 most-cited articles were compiled in a single database and the relevant data was extracted. The database included: Article Title, Scopus Citations, Year of Publication, Journal, Journal Impact Factor, Authors, Number of Authors, Department Affiliation, Number of Institutions, Country of Origin, Study Topic, Study Design, Sample Size, Open Access, Non-Original Articles, Patient/Participants Age, Gender, Symptoms, Signs, Co-morbidities, Complications, Imaging Modalities Used and outcome.

Emerging Microbes and Infections Impact Factor 2024-2025 - ResearchHelpDesk - Emerging Microbes and Infections - As an international peer-reviewed journal, the mission of Emerging Microbes & Infections (EMI) is to provide a new integrated forum to allow for the timely dissemination of a large amount of information gathered about microbes and infections, especially ones associated with increasing biological and clinical significance and pathogenic frequency. The sheer volume and complexity of such information have gone beyond the scale and scope of existing specialty journals, and thus EMI is committed to bridging the gap between scientific communities in developed and developing countries where most of the emerging microbes and infections have occurred in recent years. EMI will cover relevant topics of critical biological and clinical value including, but not limited to: epidemic surveillance; clinical manifestation; diagnosis and management; cellular and molecular pathogenesis; innate and acquired immune responses between emerging microbes and their hosts; drug discovery, and vaccine development EMI will serve microbiologists, clinicians, public health workers, drug and vaccine developers, as well as policymakers by providing them with updated knowledge encompassing microbes and infections emerging in different countries and regions throughout the world. The 2018 journal metrics for Emerging Microbes & Infections are as follows: 2-year Impact Factor: 6.212 5-year Impact Factor: 6.183 Immediacy index: 0.845 Eigenfactor score: 0.006 Article Influence Score: 2.142 Rank: 26/155 (Immunology), 15/125 (Microbiology) Emerging Microbes & Infections is currently indexed in: Biological Abstracts BIOSIS Previews Google Scholar Journal Citation Reports/Science Edition Medline PubMed PubMed Central Science Citation Index Expanded Scopus

Results of univariate and multivariate ordinal logistical regressions analyses of factors influencing impact of vaccination against COVID-19 on confusion about vaccination in general at Time 2 among staff members and students (modelling the probability of increasing impact).

Emerging Microbes and Infections Acceptance Rate - ResearchHelpDesk - Emerging Microbes and Infections - As an international peer-reviewed journal, the mission of Emerging Microbes & Infections (EMI) is to provide a new integrated forum to allow for the timely dissemination of a large amount of information gathered about microbes and infections, especially ones associated with increasing biological and clinical significance and pathogenic frequency. The sheer volume and complexity of such information have gone beyond the scale and scope of existing specialty journals, and thus EMI is committed to bridging the gap between scientific communities in developed and developing countries where most of the emerging microbes and infections have occurred in recent years. EMI will cover relevant topics of critical biological and clinical value including, but not limited to: epidemic surveillance; clinical manifestation; diagnosis and management; cellular and molecular pathogenesis; innate and acquired immune responses between emerging microbes and their hosts; drug discovery, and vaccine development EMI will serve microbiologists, clinicians, public health workers, drug and vaccine developers, as well as policymakers by providing them with updated knowledge encompassing microbes and infections emerging in different countries and regions throughout the world. The 2018 journal metrics for Emerging Microbes & Infections are as follows: 2-year Impact Factor: 6.212 5-year Impact Factor: 6.183 Immediacy index: 0.845 Eigenfactor score: 0.006 Article Influence Score: 2.142 Rank: 26/155 (Immunology), 15/125 (Microbiology) Emerging Microbes & Infections is currently indexed in: Biological Abstracts BIOSIS Previews Google Scholar Journal Citation Reports/Science Edition Medline PubMed PubMed Central Science Citation Index Expanded Scopus

Contextual influences supporting quotes by participant (with participant number and engagement with vaccination).

Emerging Microbes and Infections Abbreviation ISO4 - ResearchHelpDesk - Emerging Microbes and Infections - As an international peer-reviewed journal, the mission of Emerging Microbes & Infections (EMI) is to provide a new integrated forum to allow for the timely dissemination of a large amount of information gathered about microbes and infections, especially ones associated with increasing biological and clinical significance and pathogenic frequency. The sheer volume and complexity of such information have gone beyond the scale and scope of existing specialty journals, and thus EMI is committed to bridging the gap between scientific communities in developed and developing countries where most of the emerging microbes and infections have occurred in recent years. EMI will cover relevant topics of critical biological and clinical value including, but not limited to: epidemic surveillance; clinical manifestation; diagnosis and management; cellular and molecular pathogenesis; innate and acquired immune responses between emerging microbes and their hosts; drug discovery, and vaccine development EMI will serve microbiologists, clinicians, public health workers, drug and vaccine developers, as well as policymakers by providing them with updated knowledge encompassing microbes and infections emerging in different countries and regions throughout the world. The 2018 journal metrics for Emerging Microbes & Infections are as follows: 2-year Impact Factor: 6.212 5-year Impact Factor: 6.183 Immediacy index: 0.845 Eigenfactor score: 0.006 Article Influence Score: 2.142 Rank: 26/155 (Immunology), 15/125 (Microbiology) Emerging Microbes & Infections is currently indexed in: Biological Abstracts BIOSIS Previews Google Scholar Journal Citation Reports/Science Edition Medline PubMed PubMed Central Science Citation Index Expanded Scopus

Results of univariate and multivariate ordinal logistical regressions analyses of factors influencing impact of vaccination against COVID-19 on confusion about vaccination in general at Time 1 among staff members and students (modelling the probability of increasing impact).

AimWithin the context of increasing mental distress noted since the beginning of the COVID19 pandemic, the study aims at analysing the relationship between mental health, vaccine distrust and vaccine hesitancy in South Africa.Subject and methodsThe study uses nationally representative panel data of 3241 individuals interviewed prior to and during the COVID19 pandemic. The study uses a range of regression techniques including logit, mediation and gradient-boosted causal mediation models to identify the causal relationship while accounting for selection bias.ResultsThe results of multivariate logit regression reveal that vaccine distrust is the most important predictor of vaccine hesitancy [Coeff: 3.420, CI 3.122, 3.717]. Mental distress is not found to be a significant driver in a fully specified logit model, pointing to the need to analyse the pathways through which mental distress impacts vaccine hesitancy. The mediation regression undertaken for this purpose finds that the mental distress has a positive and significant association with vaccine distrust [Coeff: 0.027, CI: 0.0029, 0.052]. The increased vaccine distrust in turn results in increased vaccine hesitancy [Coeff: 0.661, CI: 0.611, 0.711]. The results of mediation regression therefore indicate strong and significant mediation effects, whereby mental health effects vaccine hesitancy through the mediating variable of vaccine distrust. These results are robust to the gradient boosted causal mediation model which establishes strong and significant indirect effects [Coeff: 0.015, CI: 0.01, 0.019], whereby mental health effects vaccine hesitancy through the mediating variable of vaccine distrust.ConclusionThe study concludes that mental health impacts on vaccine intention through the mediating role of vaccine distrust. The findings indicate that individuals at high risk of depression are more concerned regarding the safety of vaccines, which in turn feeds into vaccine hesitancy. Therefore, depressive symptoms impact on vaccine hesitancy through the mediating factor of vaccine distrust.

BackgroundSince the global epidemic of the coronavirus disease 2019 (COVID-19), a large number of immunological studies related to COVID-19 have been published in various immunology journals. However, the results from these studies were discrete, and no study summarized the important immunological information about COVID-19 released by these immunology journals. This study aimed to comprehensively summarize the knowledge structure and research hotspots of COVID-19 published in major immunology journals through bibliometrics.MethodsPublications on COVID-19 in major immunology journals were obtained from the Web of Science Core Collection. CiteSpace, VOSviewer, and R-bibliometrix were comprehensively used for bibliometric and visual analysis.Results1,331 and 5,000 publications of 10 journals with high impact factors and 10 journals with the most papers were included, respectively. The USA, China, England, and Italy made the most significant contributions to these papers. University College London, National Institute of Allergy and Infectious Diseases, Harvard Medical School, University California San Diego, and University of Pennsylvania played a central role in international cooperation in the immunology research field of COVID-19. Yuen Kwok Yung was the most important author in terms of the number of publications and citations, and the H-index. CLINICAL INFECTIOUS DISEASES and FRONTIERS IN IMMUNOLOGY were the most essential immunology journals. These immunology journals mostly focused on the following topics: “Delta/Omicron variants”, “cytokine storm”, “neutralization/neutralizing antibody”, “T cell”, “BNT162b2”, “mRNA vaccine”, “vaccine effectiveness/safety”, and “long COVID”.ConclusionThis study systematically uncovered a holistic picture of the current research on COVID-19 published in major immunology journals from the perspective of bibliometrics, which will provide a reference for future research in this field.

• GDP  =  gross domestic product; I$  =  international dollars. Values represent the added cost of the 9-valent HPV vaccine at which the incremental cost-effectiveness ratio (compared to current 2- or 4-valent vaccines) would be equal to 1x per capita GDP in each country.† Base case scenario  =  some benefits to prevent cervical cancer with unidentifiable types and multiple infections, defined as a function of the prevalence of the five targeted HPV types relative to the prevalence of all non-16/18 types, with 37.4% cross-protection against non-vaccine types.Impact of discount rate on thresholds of incremental cost (I$) per vaccinated girl associated with the 9-valent vaccine*.

The factors influencing respondents with risk(score>9) attitude to the vaccination.

Base scenario: Coverage 70%, boosting to age 50, with 80% completion rates to boosters, no tapering in effect over time, and with an adult catch-up program in 18–30 years covering 50% of the population of that age, rate vaccination  = 0.3/3mths, vaccine effect on VL in 100% of people, duration of vaccine effect 5 years, age of introduction 15. For each row, one characteristic is made different from the base scenario. 95% CI shown in Table S1, along with further comparisons.Mean over 2040–2060 of on-going vaccine effect, HIV incidence (per 1000 person years and death rate (/100 person years) in the whole population, according to variations in vaccine implementation characteristics.

Communities that are historically marginalized and minoritized were disproportionately impacted by the COVID-19 pandemic due to long-standing social inequities. It was found that those who experience social vulnerabilities faced a heightened burden of COVID-19 morbidities and mortalities and concerningly lower rates of COVID-19 vaccination. The CDC’s Social Vulnerability Index (CDC-SVI) is a pivotal tool for planning responses to health crises such as the COVID-19 pandemic. This study explores the associations between CDC-SVI and its corresponding themes with COVID-19 vaccine uptake in Nevada counties. Additionally, the study discusses the utility of the CDC-SVI in the context of equitable vaccine uptake in a pandemic setting. We examined the linear association between the 2020 CDC-SVI (including the composite score and the four themes) and COVID-19 vaccine uptake (including initial and complete vaccinations) for the seventeen Nevada counties. These associations were further examined for spatial-varied effects. Each CDC-SVI theme was negatively correlated with initial and complete COVID-19 vaccine uptake (crude) except for minority status, which was positively correlated. However, all correlations were found to be weak. Excessive vaccination rates among some counties are not explained by the CDC-SVI. Overall, these findings suggest the CDC-SVI themes are a better predictor of COVID-19 vaccine uptake than the composite SVI score at the county level. Our findings are consistent with similar studies. The CDC-SVI is a useful measure for public health preparedness, but with limitations. Further understanding is needed of which measures of social vulnerability impact health outcomes.

Incidence rate ratios for invasive pneumococcal disease, under 5 years of age, PCV13 non-PCV10 serotypes, comparison of pre-vaccination period with three post-vaccination periods.

BackgroundSince the global epidemic of the coronavirus disease 2019 (COVID-19), a large number of immunological studies related to COVID-19 have been published in various immunology journals. However, the results from these studies were discrete, and no study summarized the important immunological information about COVID-19 released by these immunology journals. This study aimed to comprehensively summarize the knowledge structure and research hotspots of COVID-19 published in major immunology journals through bibliometrics.MethodsPublications on COVID-19 in major immunology journals were obtained from the Web of Science Core Collection. CiteSpace, VOSviewer, and R-bibliometrix were comprehensively used for bibliometric and visual analysis.Results1,331 and 5,000 publications of 10 journals with high impact factors and 10 journals with the most papers were included, respectively. The USA, China, England, and Italy made the most significant contributions to these papers. University College London, National Institute of Allergy and Infectious Diseases, Harvard Medical School, University California San Diego, and University of Pennsylvania played a central role in international cooperation in the immunology research field of COVID-19. Yuen Kwok Yung was the most important author in terms of the number of publications and citations, and the H-index. CLINICAL INFECTIOUS DISEASES and FRONTIERS IN IMMUNOLOGY were the most essential immunology journals. These immunology journals mostly focused on the following topics: “Delta/Omicron variants”, “cytokine storm”, “neutralization/neutralizing antibody”, “T cell”, “BNT162b2”, “mRNA vaccine”, “vaccine effectiveness/safety”, and “long COVID”.ConclusionThis study systematically uncovered a holistic picture of the current research on COVID-19 published in major immunology journals from the perspective of bibliometrics, which will provide a reference for future research in this field.

Primary reason for refusal of the COVID-19 vaccine, among unvaccinated respondents, by province.

Linear probability model on psychological, sociological, and environmental factors for intention to give polio vaccine to children.

Cumulative deaths due to COVID from May 5th, 2021 to December 29, 2021 forecasted for various lockdown and vaccination scenarios.